Format

Send to

Choose Destination
Ocul Immunol Inflamm. 2009 Nov-Dec;17(6):431-3. doi: 10.3109/09273940903267936.

Fluocinolone acetonide intravitreal implants in Vogt-Koyanagi-Harada disease.

Author information

1
F.I. Proctor Foundation, University of California, San Francisco, California 94143-0412, USA.

Abstract

PURPOSE:

To describe the use of fluocinolone acetonide implants (Retisert) in Vogt-Koyanagi-Harada disease (VKH).

DESIGN:

Interventional case series.

METHODS:

Retrospective review of medical records.

RESULTS:

Two patients with VKH requiring high-dose systemic corticosteroid therapy to control their inflammation and bilateral serous retinal detachments received bilateral fluocinolone acetonide implants. Upon tapering of systemic corticosteroids, one patient had recurrent serous retinal detachments and the other patient's anterior chamber and vitreous inflammation returned.

CONCLUSIONS:

The authors' experience with fluocinolone acetonide implants in VKH has been mixed with an inability to fully taper off of systemic corticosteroids.

PMID:
20001265
DOI:
10.3109/09273940903267936
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center